Sep 29, 2022 / 06:30PM GMT
Matt Kaplan - Ladenburg Thalmann & Co. Inc - MD - Healthcare Research
I'm Matt Kaplan with Ladenburg. And it's my pleasure to introduce our next presenting company, Eledon. Presenting for Eledon today is the CEO, DA Gros; and also Steve Perrin as well, the Chief Scientific Officer.
Maybe first, you can give us just a little bit of a background overview if people aren't familiar with Eledon, just a background on the company and what you're focused on.
DA Gros - Eledon Pharmaceuticals, Inc. - CEO
Sure. So first, it's a pleasure to be here. Thank you very much for having invited us. We'll be -- I'd like to remind you we'll be making forward-looking statements. So please review our disclaimers in our public filings.
Eledon is focused on the development of anti-CD40 ligand antibodies. Our primary focus is around immunology. Today, our lead asset tegoprubart has completed a Phase 2 in ALS. And we have ongoing study in kidney transplantation, islet cell transplantation, and IgA Nephropathy.
Eledon Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript
Sep 29, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers